

India emerging as favourable destination to conduct clinical trials: PwC-USAIC Report

03 May 2023 | News

Private sector is a well-suited channel for the top biopharma to conduct more efficient clinical trials

Through several key drivers, India is emerging as a favourable destination to conduct clinical trials, as per a joint report by PwC India & USAIC (US-India Chamber of Commerce) titled, **“Clinical Trial opportunities in India”**. The report was released at the USAIC BioPharma & Healthcare Summit held virtually on May 3.

Biopharma can benefit from the critical enablers of innovation in the private healthcare system in India and leverage the rapidly expanding healthcare infrastructure in the country.

According to the report, the private sector is a well-suited channel for the top biopharma to conduct more efficient clinical trials with easier and faster access to investigators and patients.

Indian states with high disease prevalence (e.g., cancer) also have the most number of tier-1 cities, with advanced medical infrastructure and availability of investigators. Targeting these states can provide biopharma companies with faster access to patients, sites, and investigators.

India has an overall clinical trial participation of ~3% but contributes upwards of 15% to the global burden of most high prevalent diseases (e.g., respiratory infections, cardiovascular, diabetes, cervical cancer), representing an untapped potential for top pharma.

Top biopharma should align their strategy towards tier-1 cities (e.g., Mumbai, Delhi, Bengaluru, Chennai) where the higher bed capacity, number of doctors, and presence of tertiary care multi-city hospitals can support enablement efforts of running faster and more efficient clinical trials.